Basic Information
| LncRNA/CircRNA Name | CASC9 |
| Synonyms | cancer susceptibility candidate 9 |
| Region | GRCh38_8:75223404-75324741 |
| Ensemble | ENSG00000249395 |
| Refseq | NR_103848 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | other |
| Sample | blood |
| Expression Pattern | up-regulated |
| Function Description | control samples showed significantly lower CASC9 expression than carcinoma tissue samples (P < 0.001); the low CASC9 expression group had a higher survival rate than the high CASC9 expression group (P = 0.011), and the patient group showed significantly increased expression of serum CASC9.High CASC9 expression is beneficial in the prognosis of HCC patients. |
| Pubmed ID | 31908394 |
| Year | 2019 |
| Title | Diagnostic and Prognostic Value of lncRNA Cancer Susceptibility Candidate 9 in Hepatocellular Carcinoma |
External Links
| Links for CASC9 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |